Today's Most Volatile Stocks ( SKUL, CTIC, PTSX, RGDX )

Los Angelas, CA -- (SBWIRE) -- 09/14/2012 -- Skullcandy, Inc. (NasdaqNM:SKUL) reported EPS of 0.763. For the Current Fiscal year, the company is expected to report EPS of 1.15. For the Next Quarter and Next Year, the company is expected to report EPS of 0.61 and 1.43 respectively. At Current Market Price, SKUL is in distance of -21.60% from its 50-day Moving Average price of $15.2049 and -18.66% from its 200-day Moving Average price of $14.6551. Shares of headphone maker Skullcandy were clobbered Thursday after Morgan Stanley analyst Jay Sole cut his rating on the stock to Equal Weight from Overweight, with a new price target of $15, down from $21. He also cut estimates on the company: For 2012, he goes to $1.12, from $1.16; for 2013, he now sees $1.40, down from $1.55. “Channel checks challenge our prior thesis of rising prices and stable market share,” Sole writes in a research note. “Key SKUL product ASPs are falling unexpectedly and the Beats by Dr. Dre brand is taking more share than expected. We reduce EPS and now see only balanced risk/reward.”SKUL has been the subject of a number of other recent research reports. Analysts at Craig Hallum reiterated a “buy” rating on shares of Skullcandy in a research note to investors. Skullcandy, Inc. develops and distributes headphones and other audio accessories to retailers throughout the United States and to distributors in various countries worldwide.

Click Here For Free Analysist View Here

Cell Therapeutics (NCM:CTIC) reported EPS of -3.126. For the Current Fiscal year, the company is expected to report EPS of -3.00. For the Next Quarter and Next Year, the company is expected to report EPS of -0.50 and -2.50 respectively. At Current Market Price, CTIC is in distance of +27.63% from its 50-day Moving Average price of $2.3054 and -31.00% from its 200-day Moving Average price of $4.2646. Cell Therapeutics Inc(NASDAQ:CTIC) stock fell 1.47% to $3.33. The company announced the initiation of the commercial launch of Pixuvri in the European Union yesterday. Pixuvri was approved by EU regulators in May for the treatment of aggressive B-cell non-Hodgkin lymphoma, or NHL. Approximately 37,000 new cases of aggressive B-cell NHL are diagnosed in the EU every year.

Click Here For Free Analysist View Here

Shares of Point.360 (NCM:PTSX) are trading at $1.22 and is +96.86% from its 50-day Moving Average price of $0.6197 and +80.93% from its 200-day Moving Average price of $0.6743. The average trading volume is 8309 shares and its market capitalization is $12.8M. Point.360 (PTSX), a leading provider of integrated media management services, today announced results for the three and twelve month periods ended June 30, 2012, including sales of $35.0 million and income per share of $0.04 for the twelve months ended June 30, 2012. For the quarter ended June 30, 2012, the Company's sales were $9.0 million generating income of $0.06 per share. The Company also reported $4.5 million of earnings before interest, taxes, depreciation and amortization and non-cash charges (EBITDAN) for the twelve-month period, and EBITDAN of $1.5 million for the three-month period.Revenue for the quarter ended June 30, 2012 totaled $9.0 million compared to $8.6 million in the same quarter last year. Revenues for the twelve months ended June 30, 2012 were $35.0 million compared to $35.2 million last year. Fluctuations between the periods were due to the timing of service deliveries.

Click HereFor Free Analysist View Here

Shares of Response Genetics (NCM:RGDX) are trading at $1.23 and is +34.53% from its 50-day Moving Average price of $0.9143 and -15.40% from its 200-day Moving Average price of $1.4539. The average trading volume is 18502 shares and its market capitalization is $30.5M. Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has entered into a purchase agreement with GlaxoSmithKline and one of its existing significant stockholders to raise $8.8 million from the private placement of 8,000,000 newly issued shares of its common stock at a purchase price of $1.10 per share. The signing of the purchase agreement and closing of the financing occurred today, Thursday, September 13, 2012.

Click Here For Free Analysist View Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com